NovoCure Limited logo

NovoCure LimitedNASDAQ: NVCR

Profile

Sector:

Healthcare

Country:

Jersey

IPO:

01 October 2015

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.76 B
-86%vs. 3y high
79%vs. sector
-vs. 3y high
-vs. sector
-82%vs. 3y high
81%vs. sector
-86%vs. 3y high
48%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:24:11 GMT
$16.22-$0.20(-1.22%)

Dividend

No data over the past 3 years
$155.09 M$153.05 M
$155.09 M-$30.57 M

Analysts recommendations

Institutional Ownership

NVCR Latest News

NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript
seekingalpha.com30 October 2024 Sentiment: NEUTRAL

NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jason Bednar - Piper Sandler Jonathan Chang - Leerink Partners Emily Bodnar - H.C. Wainwright Jessica Fye - JPMorgan Operator Good day, and thank you for standing by.

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
zacks.com30 October 2024 Sentiment: POSITIVE

NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago.

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
zacks.com16 October 2024 Sentiment: POSITIVE

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
businesswire.com15 October 2024 Sentiment: POSITIVE

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. “Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a.

Why NovoCure Stock Dived by 13% This Week
fool.com06 September 2024 Sentiment: NEGATIVE

The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025.

Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet
zacks.com16 August 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade
zacks.com30 July 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
zacks.com25 July 2024 Sentiment: POSITIVE

NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research02 May 2024 Sentiment: POSITIVE

NovoCure (NVCR) reported a quarterly loss of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.43. This is an improvement from the loss of $0.50 per share reported a year ago.

NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research01 April 2024 Sentiment: POSITIVE

NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • 1(current)
  • 2
  • 3

What type of business is NovoCure Limited?

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

What sector is NovoCure Limited in?

NovoCure Limited is in the Healthcare sector

What industry is NovoCure Limited in?

NovoCure Limited is in the Medical Devices industry

What country is NovoCure Limited from?

NovoCure Limited is headquartered in Jersey

When did NovoCure Limited go public?

NovoCure Limited initial public offering (IPO) was on 01 October 2015

What is NovoCure Limited website?

https://www.novocure.com

Is NovoCure Limited in the S&P 500?

No, NovoCure Limited is not included in the S&P 500 index

Is NovoCure Limited in the NASDAQ 100?

No, NovoCure Limited is not included in the NASDAQ 100 index

Is NovoCure Limited in the Dow Jones?

No, NovoCure Limited is not included in the Dow Jones index

When was NovoCure Limited the previous earnings report?

No data

When does NovoCure Limited earnings report?

The next expected earnings date for NovoCure Limited is 21 February 2025